Emibetuzumab Biosimilar – Anti-MET, RCCP2 mAb – Research Grade

Description of Emibetuzumab Biosimilar - Anti-MET, RCCP2 mAb - Research Grade

Introduction

Emibetuzumab Biosimilar, also known as Anti-MET, RCCP2 mAb, is a monoclonal antibody that targets the MET receptor, a protein involved in cell growth and survival. It is a biosimilar of the original emibetuzumab, which has been approved for the treatment of metastatic colorectal cancer. In this article, we will discuss the structure, activity, and potential applications of Emibetuzumab Biosimilar.

Structure of Emibetuzumab Biosimilar

Emibetuzumab Biosimilar is a monoclonal antibody, meaning it is made from identical immune cells that are all clones of a unique parent cell. It is a humanized antibody, meaning it is derived from non-human sources but has been modified to be more similar to human antibodies. The antibody is composed of two heavy chains and two light chains, each containing a variable region that binds to the MET receptor and a constant region that determines the antibody’s function.

Activity of Emibetuzumab Biosimilar

Emibetuzumab Biosimilar works by binding to the MET receptor on the surface of cancer cells. This binding prevents the activation of the MET receptor, which is responsible for promoting cell growth and survival. By blocking this pathway, Emibetuzumab Biosimilar can inhibit the growth and spread of cancer cells.

In addition to its direct effect on

cancer cells, Emibetuzumab Biosimilar also has an indirect anti-tumor activity. The MET receptor is often overexpressed in cancer cells, making it a potential therapeutic target. By targeting the MET receptor, Emibetuzumab Biosimilar can also activate the immune system to recognize and destroy cancer cells.

Applications of Emibetuzumab Biosimilar

Emibetuzumab Biosimilar is currently being studied as a potential treatment for various types of cancer, including colorectal, gastric, and lung cancer. It has shown promising results in preclinical studies and is currently in clinical trials for these indications.

In addition to its potential as a cancer treatment, Emibetuzumab Biosimilar may also have applications in other diseases. The MET receptor is involved in various cellular processes, including wound healing and tissue regeneration. Therefore, Emibetuzumab Biosimilar may have potential in treating conditions such as fibrosis and liver diseases.

Conclusion

Emibetuzumab Biosimilar is a promising monoclonal antibody that targets the MET receptor, a protein involved in cancer cell growth and survival. Its unique structure and mechanism of action make it a potential treatment for various types of cancer and other diseases. Further research and clinical trials are needed to fully understand the potential of Emibetuzumab Biosimilar and its role in improving patient outcomes.

SDS-PAGE for Emibetuzumab Biosimilar - Anti-MET, RCCP2 mAb

Emibetuzumab Biosimilar - Anti-MET, RCCP2 mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.